TR
EN
RU
AR
FR
_2a1.jpg)
Atrial fibrillation is the most common serious heart arrhythmia in the world, affecting tens of millions of people and raising the risk of stroke fivefold compared with a normal heart rhythm. The condition causes the heart's upper chambers to beat chaotically instead of in coordinated sequence, producing an irregular heartbeat that can range from barely noticeable to severely debilitating. With the right diagnosis, personalised treatment, and long-term rhythm management, most people with AFib live full and active lives.
What Is Atrial Fibrillation?
Atrial fibrillation (AFib or AF) is a cardiac arrhythmia in which the electrical signals that normally coordinate the heartbeat become disorganised, causing the two upper chambers of the heart — the atria — to quiver rapidly and irregularly instead of contracting in a controlled, synchronised beat. Rather than receiving a steady signal from the sinoatrial node (the heart's natural pacemaker), the atria are bombarded by hundreds of chaotic electrical impulses per minute. The atrioventricular node filters some of these signals before they reach the ventricles, but the result is still an irregular and often rapid ventricular response — the hallmark of AFib.
AFib is not a single condition but a spectrum. Cardiologists classify it by how it behaves over time.
Paroxysmal Atrial Fibrillation
Paroxysmal atrial fibrillation refers to episodes that start and stop on their own, typically within 48 hours, though they can last up to seven days. Between episodes, the heart returns to a normal sinus rhythm without intervention. Paroxysmal AFib is often the earliest stage of the condition and may go undetected for years because episodes can be brief and symptom-free. Despite its intermittent nature, paroxysmal AFib carries the same stroke risk as persistent forms and requires the same attention to anticoagulation.
Persistent and Long-Standing Persistent AFib
Persistent AFib lasts longer than seven days and does not terminate spontaneously — it requires medical or electrical intervention (cardioversion) to restore normal rhythm. When AFib has been continuous for more than twelve months, it is classified as long-standing persistent. At this stage, structural and electrical changes in the atria make rhythm restoration progressively more difficult.
Permanent AFib
In permanent AFib, a decision has been made — jointly by the patient and their cardiologist — to stop attempting to restore sinus rhythm and instead focus on controlling the ventricular rate and managing stroke risk. This is not a clinical failure but a pragmatic management strategy when rhythm control proves unsustainable.
Symptoms of Atrial Fibrillation
AFib symptoms vary widely between individuals. Some people experience significant symptoms that interfere with daily life; others have no symptoms at all, and their condition is discovered incidentally on an ECG performed for another reason.
Common symptoms include:
- Palpitations — a fluttering, pounding, or racing sensation in the chest
- Shortness of breath, especially on exertion or when lying flat
- Fatigue and a generalised reduction in exercise tolerance
- Dizziness or lightheadedness
- Chest discomfort or pressure
- Anxiety associated with awareness of an abnormal heartbeat
- Reduced ability to perform physical activities that were previously manageable
When AFib causes the ventricles to beat very rapidly — a rate above 100 beats per minute at rest — symptoms tend to be more pronounced. In patients with pre-existing heart disease, rapid AFib can trigger acute heart failure or angina. Symptom severity does not reliably predict the severity of the underlying arrhythmia: some people with highly symptomatic paroxysmal AFib have structurally normal hearts, while others with permanent AFib and significant rate control problems may report only mild fatigue.
Causes and Risk Factors
Atrial fibrillation arises from a combination of electrical and structural changes in the heart, usually in the context of identifiable risk factors. The most common underlying cardiac conditions associated with AFib include:
- Hypertension— the single most prevalent modifiable risk factor for AFib
- Coronary artery disease and prior heart attack
- Heart valve disease, particularly mitral valve disease
- Heart failure and cardiomyopathy
- Congenital heart disease
Important non-cardiac and lifestyle-related risk factors include:
- Hyperthyroidism — a reversible cause that must be excluded in every new diagnosis
- Obstructive sleep apnoea — an increasingly recognised and underdiagnosed driver of AFib
- Excessive alcohol consumption (holiday heart syndrome)
- Obesity and type 2 diabetes
- Stimulant use, acute infection, major surgery, or pulmonary embolism as acute triggers
- Advancing age — AFib affects fewer than one percent of adults under 60 but more than ten percent of those over 80
- Family history of AFib
Diagnosing Atrial Fibrillation
The definitive diagnosis of AFib requires cardiac rhythm documentation, typically beginning with an electrocardiogram. Identifying the correct arrhythmia type is essential before any treatment decision is made, as different arrhythmias require different management approaches.
Atrial Fibrillation ECG
The definitive diagnosis of AFib is made on an electrocardiogram (ECG). The atrial fibrillation ECG has a characteristic appearance: there are no distinct P waves (which normally represent organised atrial contraction), replaced instead by a chaotic baseline of fibrillatory waves, and the R-R intervals between ventricular beats are irregularly irregular — meaning the spacing between beats varies with no discernible pattern. This ECG finding is pathognomonic for AFib and distinguishes it clearly from other arrhythmias.
A standard 12-lead ECG captures only a brief snapshot of cardiac rhythm, which means paroxysmal AFib can easily be missed if the patient is in sinus rhythm at the time of recording. For patients with intermittent palpitations, ambulatory monitoring options include:
- Holter monitors — continuous recording over 24 to 48 hours
- Extended event recorders or patch monitors — capturing rhythm over 7 to 30 days
- Implantable loop recorders — placed under the skin in a minor procedure, monitoring rhythm for up to three years and offering the highest sensitivity for detecting infrequent paroxysmal episodes
Additional Investigations
Once AFib is confirmed, further investigations identify the underlying cause and guide treatment decisions:
- Blood tests — thyroid function, full blood count, renal function, liver function, and coagulation screen
- Transthoracic echocardiography — assesses cardiac structure, valve function, and ejection fraction
- Transoesophageal echocardiography — provides detailed views of the left atrial appendage to exclude thrombus before cardioversion
- Blood pressure measurement and 24-hour ambulatory blood pressure monitoring
- Exercise testing where exertional symptoms or coronary disease are suspected
Atrial Fibrillation Treatment
Treatment for atrial fibrillation has two parallel objectives: reducing the risk of stroke and managing the arrhythmia itself. These goals are addressed simultaneously but through different therapeutic strategies.
Stroke Prevention and Anticoagulation
Because AFib allows blood to pool in the left atrial appendage and form clots that can travel to the brain, anticoagulation is the most important intervention for most AFib patients. Stroke risk assessment is made using the CHA₂DS₂-VASc score, which assigns points for:
- Heart failure
- Hypertension
- Age 75 or older (two points) or age 65–74 (one point)
- Diabetes
- Prior stroke or TIA (two points)
- Cardiovascular disease
- Female sex
Most guidelines recommend anticoagulation for men with a score of one or above and women with a score of two or above. Direct oral anticoagulants (DOACs) — including apixaban, rivaroxaban, edoxaban, and dabigatran — are the preferred agents over warfarin because of their predictable effect, fewer drug interactions, and lower risk of intracranial bleeding. For patients in whom anticoagulation is contraindicated, left atrial appendage occlusion (LAAO) offers a catheter-based non-pharmacological alternative.
Rate Control
Rate control aims to slow the ventricular response to AFib, relieving symptoms caused by a fast heart rate and protecting the heart muscle from tachycardia-induced dysfunction. Rate control agents include:
- Beta-blockers — first-line in most patients
- Rate-limiting calcium channel blockers (diltiazem, verapamil) — an alternative in patients who do not tolerate beta-blockers
- Digoxin — useful in patients with heart failure and reduced ejection fraction
The target is generally a resting heart rate below 110 beats per minute, adjusted according to symptoms and functional capacity.
Rhythm Control
Rhythm control strategies aim to restore and maintain sinus rhythm. Options include:
- Electrical cardioversion — a synchronised DC shock delivered under brief sedation that can restore sinus rhythm immediately, though recurrence is common without additional therapy
- Antiarrhythmic drugs — including flecainide, propafenone, sotalol, and amiodarone, which suppress abnormal electrical activity and reduce recurrence
- Catheter ablation (pulmonary vein isolation) — the most effective long-term rhythm control strategy for symptomatic AFib, in which radiofrequency or cryotherapy energy is delivered around the openings of the pulmonary veins to eliminate the electrical triggers that initiate AFib
Catheter ablation is now recommended earlier in the treatment pathway for symptomatic patients, ahead of multiple antiarrhythmic drug trials, in current international guidelines. Success rates for paroxysmal AFib following a single ablation procedure are approximately 70 to 80 percent at one year.
Living with Atrial Fibrillation and Long-Term Management
Long-term management of AFib extends beyond medications and procedures. Lifestyle modification is a core component of treatment: weight loss in overweight patients has been shown in clinical trials to significantly reduce AFib burden and improve ablation outcomes. Management of obstructive sleep apnoea, aggressive blood pressure control, regular aerobic exercise, alcohol reduction, and smoking cessation all contribute meaningfully to reducing recurrence and improving quality of life.
Patients with AFib benefit from structured follow-up with a cardiologist or specialist cardiac nurse to monitor rhythm, adjust anticoagulation, review medication, and respond to symptom changes. Remote monitoring via wearable devices and smartphone-based ECG applications has made it easier to document symptomatic episodes at the moment they occur, improving diagnostic precision and enabling more timely clinical decisions. Patient education — understanding the nature of the condition, the purpose of anticoagulation, and how to recognise signs of stroke — is an essential component of self-management that supports better long-term outcomes.
At Medical Park Hospitals Group, patients with atrial fibrillation are assessed and managed by dedicated cardiac electrophysiology teams with expertise across the full spectrum of AFib care — from initial ECG diagnosis and risk stratification through to catheter ablation, device implantation, and post-procedure rehabilitation. International patients receive coordinated care plans developed in collaboration with referring physicians, with full support from patient coordinators who manage appointments, interpretation, accommodation, and follow-up communication throughout their treatment journey.
.jpg)
_47f.webp)
_709.jpg)
_66c156f815f84eac81f56510dc534ab7.jpg)
Makaleye Dön.svg){kind=small}
E-Result
WhatsApp